The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.
 
Nathalie A. Johnson
Honoraria - Merck Sharp & Dohme; Roche
Consulting or Advisory Role - Abbvie; Gilead Sciences; Merck Sharp & Dohme; Roche
 
David Lavie
Consulting or Advisory Role - Abbvie; BMS; Novartis; Roche; Takeda
 
Peter Borchmann
Honoraria - BMS Germany; MSD Oncology
Research Funding - MSD Oncology (Inst); Takeda (Inst)
 
Gareth Gregory
Consulting or Advisory Role - Clinigen Group; Janssen; Roche/Genentech; Sandoz-Novartis
Speakers' Bureau - Abbvie; Roche/Genentech
Research Funding - BeiGene; Janssen; Merck
Expert Testimony - Janssen
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Novartis; Roche/Genentech
 
Alex Francisco Herrera
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Genmab; Karyopharm Therapeutics; Merck; Regeneron; Seagen; Takeda; Tubulis GmbH
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Kite, a Gilead company (Inst); Merck (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Leonard Minuk
No Relationships to Disclose
 
Vladan Vucinic
Honoraria - Bristol-Myers Squibb/Celgene; MSD
 
Philippe Armand
Honoraria - Merck
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; C4 Therapeutics; Celgene; Enterome; Epizyme; Genentech/Roche; GenMab; Merck Sharp & Dohme; Regeneron; Tessa Therapeutics
Research Funding - Adaptive Biotechnologies (Inst); Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); igm (Inst); Kite, a Gilead company (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
 
Abraham Avigdor
Honoraria - Gilead Sciences; Novartis; Roche/Genentech; Takeda
Consulting or Advisory Role - Gilead Sciences; Novartis; Roche; Takeda
 
Robin Gasiorowski
Honoraria - Abbvie; Astellas Pharma; Janssen; MSD; Novartis
 
Yair Herishanu
Honoraria - Abbvie; AstraZeneca/MedImmune; Janssen; Medison; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; Janssen
 
Colm Keane
Honoraria - BeiGene; Karyopharm Therapeutics; Roche
 
John Kuruvilla
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Karyopharm Therapeutics; Merck; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Gilead Sciences; Karyopharm Therapeutics; Merck; Monte Rosa Therapeutics; Roche; Seagen
Research Funding - AstraZeneca; Merck; Roche
Other Relationship - Karyopharm Therapeutics
 
John Palcza
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Pallavi Pillai
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Patricia Marinello
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
John Timmerman
Honoraria - Kite/Gilead
Consulting or Advisory Role - DAVA Oncology; Kite/Gilead
Research Funding - Bristol-Myers Squibb; ImmunGene; Kite, a Gilead company; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb